Arctic Bioscience will publish its financial results for the half year 2022 on Thursday 25 August, at
The same day at
Webcast details:
Date: Thursday
Time:
Format: Webcast and Q&A
Language: English
Link: https://channel.royalcast.com/landingpage/hegnarmedia/20220825_11/
Participants will be required to register to view the webcast and participate in the Q&A.
For further information, please contact:
CEO of
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
Jone R. Slinning
CFO of
Mobile: +47 948 75 469
Email: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.
https://news.cision.com/arctic-bioscience-as/r/arctic-bioscience---invitation-to-presentation-of-half-year-2022-results,c3616016
(c) 2022 Cision. All rights reserved., source